Cathy Eng’s highlights from ESMO24

The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.

This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.

Cathy Eng shared some insights from ESMO24:

BRAFV600X Bi-Dac Degrader

“Very promising re: sgle agent BRAFV600X Bi-Dac Degrader, CFT1946 from C4 Therapeutics; 97% prior BRAF tx’d (3 prior lines of therapy) from Dr. Vieto, Vall d’Hebron!”

Great discussion from Rachna Shroff

“Great discussion from Rachna Shroff, University of Arizona Cancer Center, re: Proferred Papers UGI session: LBA 62 and 40 – PANDAS for borderline resectable Pancreatic Cancer and APOLLO for HCC. Now I am finally caught up for ESMO24 Friday!”

BREAKWATER for BRAFV600E colorectal cancer is promising

“TY, Arndt Vogel, ESMO24! BREAKWATER for BRAFV600E colorectal cancer is promising. Great presentation Tabenero Josep and discussion Gallois Claire. Friendly reminder we are still enrolling.”

Phase II IAF-AKO Moonlight presented by Dr. Sylvie Lorenzen

“Agree Ducreux Michel. Going to include a few slides since complex study design. Phase II IAF-AKO Moonlight presented by Dr. Sylvie Lorenzen, ESMO24 with IO best in combo rather than sequential for HER2- met gastric adencocarcinoma.”

Chiara Cremolini presented this new trial

“I was thinking when Chiara Cremolini presented this new trial about possible options for colorectal ESMO24 the rejuvenation of amphiregulin and epiregulin in the ARIEL Study. Heinz Lenz, USC Norris Comprehensive Cancer Center had published > 8 yrs about its potential role!”

The final results of KN-811

“Finally! The final results of KN-811 as presented by the wonderful Sara Lonardi, ESMO24, Merck. Here was the original schema for those unfamiliar. Also more pronounced benefit if CPS >/= 1.”

Promising presentation from Yelena Janjigian

“Agree with Arndt Vogel. Promising presentation from Yelena Janjigian, Memorial Sloan Kettering Cancer Center, re: this multicohort phase II 1st line gastric cancer of Deruxtecan, Daiichi Sankyo US, ESMO24. Looking forward to the new trial with low dose rec: TDX-d at 5.4 mg/kg + cape (750 mg/m2 BID) + Pembro.”

Congrats Dr. S. Rao on Phase III PODIUM

“Congrats Dr. S. Rao on Phase III PODIUM for met ANC patients: (+) results for PFS! Nice discussion from Dominik Paul Modest discussing the challenges due to lack of randomized trials. However, I would not consider DCF next (SCARCE: low OS for combo).

Perfect timing! ECOG-ACRIN Cancer Research Group, EA2176, NCI CTEP Clinical Research has completed enrollment today for newly diagnosed met ANC!!! We look forward to the data!”

More posts featuring ESMO24 on oncodaily.com

Cathy Eng is a Professor of Medicine, Hematology and Oncology, and is the Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program at the Vanderbilt-Ingram Cancer Center. She also holds the David H. Johnson Endowed Chair of Surgical and Medical Oncology.

Dr. Eng was previously a Professor of Medical Oncology at The University of Texas MD Anderson Cancer Center. Her primary clinical research interests include clinical trials involving innovative drugs for the treatment of colorectal, anal, and appendiceal cancers. She has a specific interest in young colorectal cancer patients as well as the role of immunotherapy in HPV-associated cancers.

Nationally, Dr. Eng has served in multiple leadership roles for ASCO, ASCO GI, ECOG, and the NCI Rectal/Anal Task Force. She has most recently been chosen to serve as the Vice-Chair for the SWOG GI Committee and the NCI GI Steering Committee.